Remove Download Remove Outcomes Remove Wellness
article thumbnail

Alcohol and opioid use

EM SIM Cases

She completed her Emergency Medicine Residency at Carilion as well. She is interested in treating opioid and alcohol use disorders to decrease Emergency Medicine visits and harmful adverse outcomes related to substance use. Anne Ickes, DO is currently an Addiction Fellow at Virginia Tech Carilion School of Medicine.

article thumbnail

REBEL Cast Ep122 – Delayed vs Rapid Sequence Intubation in Agitated Trauma Patients

RebelEM

This helps relieve agitation/pain while maintaining spontaneous breathing and airway reflexes allowing for adequate pre-oxygenation as well as facilitates other resuscitation interventions including IV access, vasopressors, fluids, etc. that would not be possible in an agitated/combative patient.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

REBEL Reflections Episode 5: Thinking in Bets – Making Better Decisions When You Don’t Have All the Facts

RebelEM

REBEL Reflections Episode 5: Thinking in Bets – Making Better Decisions When You Don’t Have All the Facts Click here for Direct Download of the Podcast Think back to the last time someone asked you a difficult question regarding a patient on shift. Would they ever be well enough to be extubated?

article thumbnail

REBEL Cast Ep116: The CLOVERS Trial – Restrictive vs Liberal Fluids in Sepsis-Induced Hypotension

RebelEM

The secondary outcome of mortality was not statistically different however numerically favored the early use of norepinephrine. This could have influenced care the patients received as well as reporting of adverse events (i.e. This resulted in better shock control by 6hrs (76.1% Liberal: 14.9% Estimated Difference: -0.9%; 95% CI 04.4

Sepsis 100
article thumbnail

Journal Club - Emergency Department Initiated Buprenorphine for Opioid Use Disorder

Downeast Emergency Medicine

The primary outcome was enrollment in and receiving addiction treatment at 30-days post-randomization. Additional outcomes included self-reported days of illicit opioid use, urine testing for illicit opioids, HIV risk, and use of addiction treatment services. Download article summaries D’ONOFRIO ET AL. 2021; 78(3): 434-442.[

article thumbnail

The TOGETHER Trial Evaluates Fluvoxamine for COVID-19

PulmCCM

The TOGETHER trial is a well-regarded, randomised, adaptive platform trial investigating repurposed treatments for COVID-19 among high-risk, adult, outpatients. the patient had an outcome after at least 24 hours of therapy] and per-protocol [i.e., There were no major differences in the secondary outcomes, including viral clearance.

article thumbnail

Balanced Fluid Resuscitation for the Critically-Ill: the PLUS study mirrors the BaSICS

PulmCCM

Death, from any cause, within 90 days of randomization was the primary outcome. There were multiple secondary outcome measures that related to acute kidney injury, hemodynamic stability and respiratory failure. There was no statistically or clinically-significant difference in any of the primary or secondary outcomes.